Multiple sclerosis (Houndmills, Basingstoke, England)
Clinical and radiological outcomes of directed treatment transitions from Gilenya® to generic fingolimod.
Mahi A Patel, Tom G Punnen, Kevin S Shan, Morgan C McCreary, Crystal M Wright, Shanan B Munoz, Paula Hardeman, Katy W Burgess, Benjamin M Greenberg, Lindsay A Horton, Peter V Sguigna, Lauren M Tardo, Olaf Stüve, Darin T Okuda
Published: 202610.1177/13524585251401404
Abstract
BACKGROUND: Gilenya® (fingolimod), a sphingosine-1-receptor agonist, is an effective treatment for multiple sclerosis (MS). However, increased relapse activity has been observed after transitioning to generic fingolimod despite prior prolonged diseas…
Preview only. Read the full abstract at the source